title: Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
abstract: OBJECTIVE
  Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula.
  
  
  METHODS
  Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.
  
  
  RESULTS
  The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments.
  
  
  CONCLUSIONS
  These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.
authors.affiliation: Johns Hopkins Medical Institutions, Welch Center for Prevention, Epidemiology and Clinical Research, 2024 East Monument Street, Suite 2-500, Baltimore, MD 21287, United States. gdaumit@jhmi.edu
authors.forename: Gail L
authors.initials: GL
authors.lastname: Daumit
authors.forename: Donald C
authors.initials: DC
authors.lastname: Goff
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Meyer
authors.forename: Vicki G
authors.initials: VG
authors.lastname: Davis
authors.forename: Henry A
authors.initials: HA
authors.lastname: Nasrallah
authors.forename: Joseph P
authors.initials: JP
authors.lastname: McEvoy
authors.forename: Robert
authors.initials: R
authors.lastname: Rosenheck
authors.forename: Sonia M
authors.initials: SM
authors.lastname: Davis
authors.forename: John K
authors.initials: JK
authors.lastname: Hsiao
authors.forename: T Scott
authors.initials: TS
authors.lastname: Stroup
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015897:Comorbidity; D003327:Coronary Disease / Q000139:chemically induced / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D009765:Obesity / Q000139:chemically induced / Q000453:epidemiology; D017063:Outcome Assessment, Health Care; D010352:Patient Dropouts; D018570:Risk Assessment; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D012565:Schizophrenic Psychology; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents
references.citation: N Engl J Med. 2005 Sep 22;353(12):1209-23
references.pmid: 16172203
references.citation: JAMA. 2007 Jul 18;298(3):299-308
references.pmid: 17635890
references.citation: J Nerv Ment Dis. 1972 Jan;154(1):31-42
references.pmid: 4550211
references.citation: Prev Cardiol. 2004 Fall;7(4):168-75
references.pmid: 15539963
references.citation: J Clin Psychiatry. 2002 Oct;63(10):856-65
references.pmid: 12416594
references.citation: J Nerv Ment Dis. 2006 Jun;194(6):404-10
references.pmid: 16772856
references.citation: J Clin Psychiatry. 1999 Apr;60(4):215-20
references.pmid: 10221280
references.citation: J Clin Psychopharmacol. 2003 Dec;23(6):595-600
references.pmid: 14624190
references.citation: Schizophr Res. 2000 Sep 29;45(1-2):21-8
references.pmid: 10978869
references.citation: Schizophr Res. 2004 Sep 1;70(1):1-17
references.pmid: 15246458
references.citation: Circulation. 1998 May 12;97(18):1837-47
references.pmid: 9603539
references.citation: J Nerv Ment Dis. 2005 Oct;193(10):641-6
references.pmid: 16208158
references.citation: J Clin Psychopharmacol. 2001 Aug;21(4):369-74
references.pmid: 11476120
references.citation: Schizophr Res. 2008 Apr;101(1-3):273-86
references.pmid: 18258416
references.citation: Schizophr Res. 2003 Mar 1;60(1):99-100
references.pmid: 12505146
references.citation: Br J Psychiatry. 1997 Dec;171:502-8
references.pmid: 9519087
references.citation: Psychiatr Serv. 1996 Dec;47(12):1356-63
references.pmid: 9117475
references.citation: Am J Psychiatry. 2004 Aug;161(8):1334-49
references.pmid: 15285957
references.citation: Prim Care Companion J Clin Psychiatry. 2006;8(6):329-33
references.pmid: 17245453
references.citation: Schizophr Bull. 2003;29(1):15-31
references.pmid: 12908658
references.citation: Br J Psychiatry. 2003 Dec;183:534-9
references.pmid: 14645025
references.citation: J Child Adolesc Psychopharmacol. 2001 Winter;11(4):415-24
references.pmid: 11838824
references.citation: Am J Psychiatry. 1992 Sep;149(9):1189-94
references.pmid: 1503131
references.citation: Diabetes Care. 2004 Feb;27(2):596-601
references.pmid: 14747245
references.citation: Schizophr Res. 2005 Dec 1;80(1):45-53
references.pmid: 16198088
references.citation: Int Rev Psychiatry. 2005 Jun;17(3):173-80
references.pmid: 16194788
references.citation: Am J Psychiatry. 1999 Nov;156(11):1686-96
references.pmid: 10553730
references.citation: Clin Pharmacol Ther. 1985 Jun;37(6):684-7
references.pmid: 2860989
references.citation: J Clin Psychiatry. 2001 May;62(5):347-9
references.pmid: 11411816
references.citation: J Nerv Ment Dis. 2003 Dec;191(12):799-805
references.pmid: 14671456
references.citation: Can J Psychiatry. 2006 Jul;51(8):480-91
references.pmid: 16933585
references.citation: Schizophr Res. 1992 Dec;8(2):93-102
references.pmid: 1360812
references.citation: Prev Chronic Dis. 2006 Apr;3(2):A42
references.pmid: 16539783
references.citation: Arch Intern Med. 1993 Jan 25;153(2):154-83
references.pmid: 8422206
references.citation: Schizophr Res. 2005 Dec 1;80(1):19-32
references.pmid: 16137860
references.citation: Schizophr Bull. 2003;29(2):393-7
references.pmid: 14552512
references.citation: J Clin Psychiatry. 2002 May;63(5):425-33
references.pmid: 12019668
references.citation: JAMA. 2001 Jul 11;286(2):180-7
references.pmid: 11448281
references.citation: Psychiatr Rehabil J. 2006 Spring;29(4):267-73
references.pmid: 16689037